Clinical Trials Logo
  1. Home
  2. Lung Cancer, Non-Small Cell
  3. NCT04581824

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Lung Cancer, Non-Small Cell Clinical Trial

Official title:
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer

Clinical Trial Summary

NSCLC comprises of approximately 84 percent (%) of all lung cancers and is often diagnosed at advanced stage due to poor prognosis. Dostarlimab is an immunoglobulin G (IgG)4 kappa humanized monoclonal antibody (mAb) that binds with high affinity to programmed cell death protein 1 (PD 1), resulting in inhibition of binding to programmed death ligand 1 (PD L1) and programmed death ligand 2 (PD L2). This study aims to compare the efficacy and safety PD-1 inhibitors dostarlimab and pembrolizumab, when administered in combination with chemotherapy (pemetrexed, cisplatin and carboplatin), in participants with non-squamous NSCLC without a known sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase-1 (ROS-1) mutation, BRAF V600E mutation, or other genomic aberration for which an approved targeted therapy is available. A total of approximately 240 participants will be enrolled in the study for a period of 5 years.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04581824
Study type Interventional
Source GlaxoSmithKline
Contact
Status Active, not recruiting
Phase Phase 2
Start date November 19, 2020
Completion date October 20, 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05598528 - Exploring the Mechanism of Primary Resistance to Third-generation EGFR-TKIs as First-line Treatment in EGFR-positive Advanced NSCLC (PRECISE Study)
Completed NCT03836469 - Retrospective Epidemiological Study of Locally Advanced Non Small Cell Lung Cancer Patients in Brazil
Completed NCT01772225 - NSCLC Burden of Illness Study N/A
Completed NCT01362296 - An Open-label Study of GSK1120212 Compared With Docetaxel in Stage IV KRAS-mutant Non-small Cell Lung Cancer Phase 2
Active, not recruiting NCT01460472 - Immunotherapy With Racotumomab in Advanced Lung Cancer Phase 3
Recruiting NCT03803137 - Volatil Organic Compounds in Exhaled Air and Sweat After Thoracic Surgery for Carcinological Resection N/A
Completed NCT00528281 - A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase Phase 1
Not yet recruiting NCT04592666 - Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer Phase 2
Terminated NCT00480025 - GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer Phase 3
Active, not recruiting NCT05784142 - Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC) Phase 2
Active, not recruiting NCT04475939 - Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced/Metastatic Non-small Cell Lung Cancer Phase 3
Withdrawn NCT01938456 - Safety and Tolerability of Trametinib in Combination With Docetaxel in Japanese Subjects With Non-small Cell Lung Cancer Phase 1
Terminated NCT04069936 - Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Nivolumab With or Without Tadalafil in Locally Advanced and Unresectable or Metastatic NSCLC Phase 2
Recruiting NCT05565378 - A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer Phase 2
Active, not recruiting NCT04986670 - NutriCare Plus a Medically Tailored Meal Intervention Among Patients With Lung Cancer N/A
Completed NCT00367679 - Pazopanib As Pre-Surgical Therapy In Treatment-Naive Subjects With Non-Small Cell Lung Cancer Phase 2
Terminated NCT00073008 - A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer Phase 2
Completed NCT00619424 - A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors Phase 1
Recruiting NCT04940936 - Shared Decision Making on Radiation Dose for Lung Malignancies N/A
Recruiting NCT02824952 - Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC Phase 2